Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGENASDAQ:BEAMNASDAQ:ETONNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$39.74+0.4%$36.51$26.20▼$63.50$1.78B1.7527,723 shs628,740 shsBEAMBeam Therapeutics$18.05-1.0%$19.92$13.53▼$35.25$1.82B2.351.44 million shs1.73 million shsETONEton Pharmaceuticals$17.07-1.6%$14.55$3.18▼$18.41$457.78M1.22185,228 shs335,618 shsTARSTarsus Pharmaceuticals$41.46-6.2%$48.26$20.08▼$57.28$1.74B0.94694,392 shs1.56 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics+6.14%+0.48%+24.47%+14.76%-25.63%BEAMBeam Therapeutics+4.71%-7.97%+17.91%-32.07%-14.21%ETONEton Pharmaceuticals+2.85%+2.24%+39.36%+0.46%+405.83%TARSTarsus Pharmaceuticals-1.49%-7.92%-4.80%-13.71%+19.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPGEApogee Therapeutics2.1161 of 5 stars3.50.00.00.02.84.20.0BEAMBeam Therapeutics2.839 of 5 stars4.51.00.00.01.72.50.6ETONEton Pharmaceuticals2.7538 of 5 stars3.53.00.00.04.10.80.6TARSTarsus Pharmaceuticals3.0241 of 5 stars4.50.00.00.03.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 3.00Buy$94.60138.05% UpsideBEAMBeam Therapeutics 3.00Buy$48.75170.08% UpsideETONEton Pharmaceuticals 3.00Buy$27.6762.08% UpsideTARSTarsus Pharmaceuticals 3.00Buy$66.3359.99% UpsideCurrent Analyst Ratings BreakdownLatest ETON, TARS, BEAM, and APGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2025BEAMBeam TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$78.00 ➝ $55.005/7/2025BEAMBeam TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $70.005/7/2025BEAMBeam TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.005/5/2025TARSTarsus PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$46.00 ➝ $51.005/2/2025TARSTarsus PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$78.00 ➝ $84.004/7/2025BEAMBeam TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/28/2025BEAMBeam TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$42.00 ➝ $42.003/19/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $26.003/19/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $24.003/19/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.003/13/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$95.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/ABEAMBeam Therapeutics$63.58M28.55N/AN/A$12.04 per share1.50ETONEton Pharmaceuticals$39.01M11.73$0.00 per share4,502.79$0.60 per share28.45TARSTarsus Pharmaceuticals$233.67M7.45N/AN/A$5.95 per share6.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$83.99M-$3.29N/AN/AN/AN/A-21.81%-20.94%N/ABEAMBeam Therapeutics-$132.53M-$4.61N/AN/AN/A-41.07%-16.22%-10.94%N/AETONEton Pharmaceuticals-$940K-$0.15N/A34.14N/A-15.81%-36.29%-16.84%N/ATARSTarsus Pharmaceuticals-$135.89M-$2.73N/AN/AN/A-103.64%-55.86%-39.28%5/14/2025 (Estimated)Latest ETON, TARS, BEAM, and APGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TARSTarsus Pharmaceuticals-$0.75N/AN/AN/A$71.19 millionN/A5/12/2025Q1 2025APGEApogee Therapeutics-$1.19-$0.95+$0.24-$0.95N/AN/A5/8/2025Q1 2025ETONEton Pharmaceuticals$0.05$0.07+$0.02-$0.06$14.33 millionN/A5/6/2025Q1 2025BEAMBeam Therapeutics-$1.11-$1.24-$0.13-$1.24$14.69 million$7.47 million5/1/2025Q1 2025TARSTarsus Pharmaceuticals-$0.69-$0.64+$0.05-$0.64$72.50 million$78.34 million3/18/2025Q4 2024ETONEton Pharmaceuticals-$0.02-$0.02N/A-$0.02$10.53 million$11.65 million3/3/2025Q4 2024APGEApogee Therapeutics-$0.94-$1.19-$0.25-$1.19N/AN/A2/25/2025Q4 2024BEAMBeam Therapeutics-$1.25-$1.09+$0.16-$1.09$16.47 million$30.00 million2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ABEAMBeam Therapeutics$0.904.99%N/AN/A N/AETONEton PharmaceuticalsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3916.39BEAMBeam TherapeuticsN/A5.695.69ETONEton PharmaceuticalsN/A1.511.41TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%BEAMBeam Therapeutics99.68%ETONEton Pharmaceuticals27.86%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics36.10%BEAMBeam Therapeutics4.20%ETONEton Pharmaceuticals16.03%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9144.88 million28.77 millionOptionableBEAMBeam Therapeutics510100.56 million79.33 millionOptionableETONEton Pharmaceuticals2026.82 million22.17 millionOptionableTARSTarsus Pharmaceuticals5042.01 million35.07 millionOptionableETON, TARS, BEAM, and APGE HeadlinesRecent News About These CompaniesEnsign Peak Advisors Inc Decreases Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 13 at 6:32 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by Schonfeld Strategic Advisors LLCMay 13 at 4:17 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by The Manufacturers Life Insurance CompanyMay 13 at 4:16 AM | marketbeat.comTarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay OffMay 12 at 12:28 PM | seekingalpha.comTudor Investment Corp ET AL Takes $769,000 Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 10 at 4:11 AM | marketbeat.comDimensional Fund Advisors LP Sells 62,658 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 10 at 3:44 AM | marketbeat.comTarsus Pharmaceuticals (TARS) to Release Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comCaxton Associates LP Buys New Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 9, 2025 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 8, 2025 | globenewswire.comCutter Capital Management LP Invests $6.23 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 8, 2025 | marketbeat.comThe Goldman Sachs Group Increases Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $51.00May 7, 2025 | marketbeat.comVoya Investment Management LLC Purchases 18,000 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 7, 2025 | marketbeat.comRaymond James Financial Inc. Acquires Shares of 19,999 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 7, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $51.00 at The Goldman Sachs GroupMay 7, 2025 | americanbankingnews.comFreestone Grove Partners LP Makes New $439,000 Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)May 6, 2025 | marketbeat.com6 Analysts Assess Tarsus Pharmaceuticals: What You Need To KnowMay 5, 2025 | benzinga.comTarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to AnalystsMay 5, 2025 | insidermonkey.comUncovering Potential: Supernus Pharmaceuticals's Earnings PreviewMay 5, 2025 | benzinga.comElanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt PaydownMay 5, 2025 | prnewswire.comTarsus Pharmaceuticals (NASDAQ:TARS) Shares Gap Down - Here's What HappenedMay 5, 2025 | marketbeat.comAnalysts Just Made A Substantial Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) ForecastsMay 4, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETON, TARS, BEAM, and APGE Company DescriptionsApogee Therapeutics NASDAQ:APGE$39.74 +0.16 (+0.40%) As of 04:00 PM EasternApogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Beam Therapeutics NASDAQ:BEAM$18.05 -0.19 (-1.04%) As of 04:00 PM EasternBeam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Eton Pharmaceuticals NASDAQ:ETON$17.07 -0.28 (-1.61%) As of 04:00 PM EasternEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Tarsus Pharmaceuticals NASDAQ:TARS$41.46 -2.74 (-6.20%) As of 04:00 PM EasternTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
